Established patent firm with exceptional pharmaceutical sector knowledge
Our client portfolio covers the spectrum of small businesses to industry leading FTSE 100 companies, including start-ups, academic research organisations, university spin-outs and venture capital funds. We have built our first-class reputation on the results we achieve for our clients and much of our new business comes through recommendations.
We have once again been ranked as one of Europe’s Leading Patent Law Firms by the Financial Times and Statista, being rated Gold in both the Chemistry & Pharmaceuticals and Biotechnology & Food categories.
The Unitary Patent & Unified Patent Court
A new system providing a Unitary Patent (UP) and Unified Patent Court (UPC) in Europe is expected to come into force towards the end of 2022. This will provide new options for European patent applications upon grant. However, it will also affect European patents (EPs) granted and validated under the current EP system, therefore all owners of European applications and patents should carefully consider their position in advance of the new system coming into force. Please contact us for further information or assistance with reviewing your portfolio.
While the UK Government has confirmed that it will not be seeking involvement in the UP/UPC system following the UK’s departure from the EU, this does not affect our ability to continue to file and prosecute EPs and UPs.